Coleman v. Medtronic, Inc.
167 Cal. Rptr. 3d 300
Cal. Ct. App.2014Background
- Medtronic manufactures Infuse, a Class III FDA premarket‑approved spinal fusion device; FDA approval covered anterior lumbar interbody fusion but not posterior lumbar interbody fusion (off‑label use).
- Medtronic allegedly promoted Infuse for posterior fusion, sponsored studies, engaged Key Opinion Leaders, and placed sales personnel in operating rooms; internal and published materials downplayed or omitted reported adverse events (excess bone growth, nerve encasement).
- In April 2009 Coleman underwent posterior fusion with Infuse and suffered unwanted bone growth and nerve injuries; he sued Medtronic alleging manufacturing defect, failure to warn, negligence, fraud and related claims.
- The trial court sustained Medtronic’s demurrer to Coleman’s third amended complaint without leave to amend on preemption grounds; Coleman appealed.
- The appellate court considered (1) express preemption under 21 U.S.C. § 360k (Riegel line), (2) implied preemption / Buckman (private enforcement of FDCA), and (3) whether state tort claims can be pleaded as parallel to federal requirements.
- Court affirmed dismissal of certain claims (fraud, intentional misrepresentation, UCL, concealment, failure‑to‑warn grounded in off‑label promotion), reversed as to other claims (strict liability failure to warn based on failure to report to FDA, negligence, and manufacturing defect) and remanded for further proceedings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether state failure‑to‑warn claim based on failing to report adverse events to FDA is preempted | Coleman: duty to report adverse events to FDA parallels federal reporting requirements and supports state strict liability/failure‑to‑warn and negligence claims | Medtronic: such claims are preempted or forfeited; private enforcement of FDA rules is barred under Buckman/§337(a) | Not preempted; state claims that parallel federal adverse‑event reporting survive (followed Stengel en banc) |
| Whether state failure‑to‑warn claim premised on off‑label promotion is preempted | Coleman: state law duty to warn covers risks from promoted off‑label use; parallels federal prohibitions on misbranding/adulteration | Medtronic: allowing state warning duties beyond FDA‑approved labeling would impose additional requirements preempted by §360k | Expressly preempted; failure‑to‑warn based on off‑label promotion would impose requirements different from FDA labeling and is barred |
| Whether negligence claims based on failure to report adverse events are preempted / cognizable | Coleman: negligence (including negligence per se) may adopt federal reporting duties as standard of care; traditional state tort law supports claim | Medtronic: negligence per se based on federal regs is effectively private enforcement of FDCA and preempted | Not preempted; negligence and negligence‑per‑se theories based on failure to report survive demurrer |
| Whether negligence claims based on off‑label promotion are preempted | Coleman: off‑label promotion that misrepresents risks creates a state tort duty of care and causation to injured patient | Medtronic: such claims are impliedly preempted as attempts to enforce FDCA or are inconsistent with federal scheme | Not preempted as to negligence theory; court found state negligence claim can parallel federal misbranding/adulteration duties and survive at pleading stage |
| Whether manufacturing‑defect claim alleging violation of FDA manufacturing/PMA requirements survives pleading / preemption challenge | Coleman: general allegation that Infuse failed to meet PMA/CGMP requirements suffices at pleading stage; discovery needed for specifics | Medtronic: plaintiff must plead specific federal requirement violated; boilerplate invoking FDA is insufficient and is preempted | Reversed dismissal as premature; manufacturing defect claim not finally preempted and remanded for discovery/clarification |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) (establishes express preemption framework for PMA Class III devices)
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (2001) (private claims that exist solely by virtue of FDCA are impliedly preempted)
- Stengel v. Medtronic, Inc., 704 F.3d 1224 (9th Cir. en banc 2013) (state failure‑to‑warn claim based on failure to report adverse events to FDA not preempted)
- Farm Raised Salmon Cases, 42 Cal.4th 1077 (2008) (state remedies parallel to federal requirements may be permitted)
- Hughes v. Boston Scientific Corp., 631 F.3d 762 (5th Cir. 2011) (state negligence claim parallel to federal reporting duties not preempted)
- Wolicki‑Gables v. Arrow Int’l, Inc., 634 F.3d 1296 (11th Cir. 2011) (requires state and federal requirements to be genuinely equivalent to avoid express preemption)
- Evraets v. Intermedics Intraocular, Inc., 29 Cal.App.4th 779 (1995) (negligence per se based on federal standard of care is cognizable under California law)